Cost-benefit analysis of a PMTCT program in Mozambique

被引:4
|
作者
Peffer, D
Osman, NB
Vaz, P
机构
[1] Minist Saude, Maputo, Mozambique
[2] Maputo Cent Hosp, Dept Obstet & Gynaecol, Maputo, Mozambique
[3] Maputo Cent Hosp, Dept Pediat, Maputo, Mozambique
关键词
HIV/AIDS; Mozambique; PMTCT; cost-effectiveness; cost-benefit; ARV; voluntary counselling and testing; infant feeding; UNAIDS cost-effectiveness tool;
D O I
10.1016/S0149-7189(02)00054-X
中图分类号
C [社会科学总论];
学科分类号
03 ; 0303 ;
摘要
The costs and benefits of a HlV/AIDS PMTCT program in a Mozambican city were calculated. The provision and non-provision of infant feeding formula were considered, along with voluntary counselling and testing, and anti-retroviral treatment with Nevirapine. Costs were calculated in monetary units and benefits as deaths averted and disability-adjusted life years. The UNAIDS cost-effectiveness tool for evaluating ARV drug and substitute feeding intervention was used. The costs of the program were compared with the costs of treating HIV-infected children. With no infant feeding formula, there would be a total savings of US$5242 and a negative cost per DALY of US$1.53 without infant feeding formula, With formula, net annual costs would be US$141,268 and cost per DALY US$38.69. Citywide, each year 132 infant deaths would be averted by use of Nevirapine and eight averted by the breastmilk replacement program. All program optins have reasonable cost-effectiveness ratios. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:433 / 445
页数:13
相关论文
共 50 条
  • [21] Beware the cost-benefit analysis
    Spence, Des
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
  • [22] Incommensurability and cost-benefit analysis
    Adler, M
    [J]. UNIVERSITY OF PENNSYLVANIA LAW REVIEW, 1998, 146 (05) : 1371 - 1418
  • [23] In Defence of Cost-Benefit Analysis
    Ergas, Henry
    [J]. AGENDA-A JOURNAL OF POLICY ANALYSIS AND REFORM, 2009, 16 (03) : 31 - 40
  • [24] Cost-benefit analysis is the key
    Kelnar, CJH
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2000, 83 (02) : 176 - 177
  • [25] Humanizing Cost-Benefit Analysis
    Sunstein, Cass R.
    [J]. EUROPEAN JOURNAL OF RISK REGULATION, 2011, 2 (01) : 3 - 7
  • [26] Equity in cost-benefit analysis
    Hahn, Robert W.
    [J]. SCIENCE, 2021, 372 (6541) : 439 - 439
  • [27] Pediatric cost-benefit analysis
    Schulze-Gattermann, H
    Illg, A
    Lesinski-Schiedat, A
    Schoenermark, M
    Bertram, B
    Lenarz, T
    [J]. LARYNGO-RHINO-OTOLOGIE, 2003, 82 (05) : 322 - 329
  • [28] Cost-benefit analysis and population
    Broome, J
    [J]. JOURNAL OF LEGAL STUDIES, 2000, 29 (02): : 953 - 970
  • [29] Cost-benefit analysis: examples
    Linn, Mott
    [J]. BOTTOM LINE, 2011, 24 (01): : 68 - 72
  • [30] Liraglutide: A Cost-Benefit Analysis
    Schoeffski, O.
    Mentrup, S.
    Lund, N.
    Pfuetzner, A.
    [J]. DIABETES STOFFWECHSEL UND HERZ, 2010, 19 (03): : 177 - 184